Bruker

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions tailored for molecular and materials research, as well as industrial and applied analysis. The company manufactures a range of scientific instruments and diagnostic tests primarily for clients in the life sciences, pharmaceutical, and biotechnology sectors. Bruker operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST), with the BSI CALID segment generating the highest revenue. The company has a significant revenue presence in the Asia Pacific region, reflecting its global reach and commitment to advancing scientific research and innovation. Additionally, Bruker Cellular Analysis focuses on cell biology, facilitating the exploration of cellular phenomes and the mastery of single-cell analysis for laboratories.

Frank Laukien

President and CEO

Rohan Thakur

President

57 past transactions

RECIPE

Acquisition in 2025
RECIPE is a clinical kit manufacturer with a focus on CE-IVD solutions for HPLC and LC-MS/MS kits. Full kits for LC-MS/MS, HPLC, and photometry are among their offerings, along with calibrators, controls, optimization mixes, internal standards, and instruments. MS/MS parameter optimization and the ensuing analytical system verification are the goals of optimization mixtures.

Terrain Bio

Seed Round in 2025
Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhance the expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines.

PrognomIQ

Series D in 2024
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Dynamic Biosensors

Acquisition in 2024
Dynamic Biosensors GmbH, based in Munich, Germany, specializes in biomolecular interaction analysis solutions. The company offers the switchSENSE platform, which features the switchSENSE Analyzer and switchSENSE Biochip, enabling label-free interaction analysis through electrically actuated switchable DNA interfaces. These products facilitate various applications, including protein-protein, DNA-protein, and DNA-DNA analysis. By utilizing switchSENSE technology, Dynamic Biosensors provides highly sensitive measurement data that helps biotechnology institutions enhance the quality of their research while reducing the time and costs associated with molecular measurements.

NovAliX

Corporate Round in 2024
NovAliX is a biotechnology company specializing in drug discovery and development services for the pharmaceutical industry. It offers a range of integrated services, including enabling chemistry and biophysical technologies, to support clients from discovery to manufacturing. Key capabilities include proprietary Surface Plasmon Resonance (SPR) technology, X-ray protein crystallography, supramolecular mass spectrometry, and advanced Nuclear Magnetic Resonance (NMR) technologies. These are used for comprehensive small molecule drug discovery, fine characterization of biologics, thorough analysis of Active Pharmaceutical Ingredients (APIs), and polymorphism studies, supporting pharmaceutical development and manufacturing teams.

NanoString Technologies

Acquisition in 2024
NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.

Spectral Instruments Imaging

Acquisition in 2024
Spectral Instruments Imaging is a company that manufactures and sells imaging systems, primarily for in-vivo optical imaging in small animals. Their products are designed to monitor disease progression, utilizing bioluminescent, fluorescent, and x-ray imaging techniques. They also offer cooled high-sensitivity cameras and software for absolute calibration and ease of use, ensuring quantifiable and reliable imaging results. Additionally, the company provides data services to support its imaging systems.

Chemspeed Technologies

Acquisition in 2024
Chemspeed Technologies AG specializes in automation solutions for research and development laboratories, enhancing productivity across various industries, including pharmaceuticals, agrochemicals, and material sciences. Established in 1997 and headquartered in Füllinsdorf, Switzerland, the company provides a range of products, including the flex platform and swing/swing XL systems, which facilitate high-throughput and high-output research workflows. Their offerings encompass workflow packages for drug discovery, catalyst research, and formulation development, supported by the AutoSuite Workflow Management Software that manages instrument control and data processing. Chemspeed also provides software for robotic tools, reactors, and various laboratory vessels, alongside application-oriented training and support services. The company's solutions are distributed through a network of partners, with additional offices in North Brunswick, New Jersey, and York, United Kingdom.

Tornado Spectral Systems

Acquisition in 2024
Tornado Spectral Systems designs and manufactures optical spectrometers specializing in Raman spectroscopy and spectral-domain optical coherence tomography (OCT). The company offers a range of products, including HyperFlux spectrometers, which excel in sample identification, detection, diagnosis, and imaging. Tornado provides optical platforms suitable for laboratory use, original equipment manufacturer (OEM) integration, and equipment upgrades, alongside nanophotonics solutions that enhance optical coherence tomography measurements for ophthalmic and material characterization applications. Founded in 2010 and based in Toronto, Canada, Tornado serves various industries, including security, defense, environmental monitoring, biomedical, and scientific research. The company is known for its innovative High Throughput Virtual Slit (HTVS) technology, which significantly improves Raman analysis sensitivity and enables real-time measurements in challenging environments, making its systems ideal for both production line and laboratory settings.

Nion

Acquisition in 2024
Nion is a technology company specializing in the development and manufacturing of electron-optical instruments, with a focus on advanced scanning transmission electron microscopes. They produce a range of products, including the u-hermes, ultrastem 200, ultrastem 500, and ultrastem 100, designed to enhance productivity and enable novel experiments. Nion works closely with customers to create customized solutions that address specific real-world challenges, combining clean, bakeable vacuum technology, modern electron optics for high resolution, and flexible design for post-installation modifications.

Elitech Group

Acquisition in 2023
ELITech Group SAS is a manufacturer and distributor of in vitro diagnostic equipment and reagents, focusing on clinical chemistry, microbiology, immunology, and molecular biology. Established in 1997 and headquartered in Puteaux, France, the company provides a comprehensive range of products, including clinical chemistry systems, open chemistry reagents, cytology and hematology products, immunology assays, and molecular diagnostics tools such as PCR instruments. ELITech Group addresses various medical conditions, including infectious diseases, cancer, cardiovascular diseases, and more, serving laboratories through both direct sales and an extensive distribution network that spans over 100 countries. By integrating specialized companies within the in vitro diagnostics sector, ELITech Group enhances clinical diagnostics and supports laboratories operating closer to patients.

Tome Biosciences

Series A in 2023
Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

MIRO Analytical

Acquisition in 2023
MIRO Analytical Technologies GmbH specializes in the manufacture of advanced laser-based gas analyzers aimed at addressing global warming and air pollution. Founded in 2018 in Dübendorf, Switzerland, as a spinoff from Empa, the company leverages cutting-edge mid-infrared gas sensing technology utilizing quantum cascade lasers (QCLs). Their innovative instruments employ direct laser absorption spectroscopy to enable precise and simultaneous detection of multiple pollutants, including carbon dioxide, methane, and nitrous oxide, while minimizing the footprint and operational costs associated with gas measurements. MIRO Analytical serves a diverse clientele, including scientists, regulatory authorities, and various industries such as chemical, pharmaceutical, oil and gas, and automotive, all of which depend on accurate gas analysis for process control, emissions monitoring, and workplace safety.

PhenomeX

Acquisition in 2023
PhenomeX is a functional cell biology company focused on advancing research by providing tools that enhance the understanding of cellular behavior. The company enables researchers to explore the full potential of each cell, offering live cell biology research solutions that deliver in-depth insights into cellular functions. By facilitating a comprehensive analysis of cell behavior, PhenomeX aims to contribute significantly to the field of functional cell biology and its applications in improving human health.

Zontal

Acquisition in 2023
ZONTAL is a leading provider of digital transformation services tailored for the life sciences industry, focusing on analytical laboratories and integrated biopharma data solutions. The company delivers a GxP-compliant data platform that streamlines communication between IT systems and laboratory devices, ensuring the preservation of digital assets at an enterprise scale. By reducing IT overhead, enabling AI and machine learning applications, and optimizing time-to-market, ZONTAL supports complex enterprises in enhancing compliance and operational efficiency. With a presence in the US, Europe, and Asia, ZONTAL collaborates with integration and service partners to provide global support to its customers across various time zones.

Mercy BioAnalytics

Series A in 2023
Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Biognosys

Acquisition in 2023
Biognosys, a spin-off from ETH Zurich, specializes in next-generation proteomics. The company offers a unique, high-resolution mass spectrometry-based solution for precise, large-scale protein quantification in biological samples. This enables more effective discovery and validation of biomarkers and drug targets, thereby advancing life science research and personalized healthcare.

Kiyatec

Series C in 2022
Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.

Haystack Oncology

Series A in 2022
Haystack Oncology is an oncology company that specializes in liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. By utilizing advanced circulating tumor DNA detection methods, the company enhances the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. Their technology focuses on identifying tumor-specific markers through blood samples, which facilitates the early detection of recurrent disease and offers increased sensitivity in monitoring residual disease post-treatment. This innovation enables healthcare teams to access cutting-edge liquid biopsy tools, thereby transforming the management of cancer and significantly improving patient care.

Navignostics

Seed Round in 2022
Navignostics is focused on improving cancer treatment by using spatial single-cell proteomics to characterize tumors. The company aims to identify the most effective therapies for individual patients, thereby enhancing personalized diagnostics and reducing patient suffering. In addition to tailoring treatments, Navignostics accelerates cancer drug development by offering critical insights into drug mechanisms and tumor characteristics, which are essential for companion diagnostic development. This approach not only enables clinicians to make informed treatment recommendations but also increases the availability of effective drugs for cancer patients. By leveraging its advanced technology and data analytics, Navignostics provides valuable services to pharmaceutical and biotech partners, ultimately contributing to better outcomes for those affected by cancer.

Inscopix

Acquisition in 2022
Inscopix, Inc., established in 2010 and located in Menlo Park, California, specializes in the development of miniature fluorescence microscopes aimed at advancing the understanding of brain function and its associated diseases. The company has pioneered technology that allows for large-scale imaging of neural activity in subjects behaving naturally. Its key products include the nVista, nVoke, and nVue systems, which facilitate groundbreaking research in areas such as calcium imaging, optogenetics, blood flow imaging, and neurotransmitter imaging. By providing innovative tools for cell-type mapping, connectivity mapping, and neural coding, Inscopix empowers neuroscientists globally to collect unprecedented data and drive new scientific discoveries related to brain health and therapeutic approaches.

Tofwerk

Corporate Round in 2022
TOFWERK, founded in Switzerland in 2002, specializes in designing and manufacturing high-performance analytical instrumentation utilizing time-of-flight mass spectrometry (TOFMS) technology. The company offers a range of research mass spectrometers that deliver enhanced speed and sensitivity for various laboratory and field applications. TOFWERK is committed to environmental protection, providing solutions for chemical analysis through custom spectrometer systems that employ focused ion beam technology. These systems enable real-time online analysis of volatile organic and inorganic compounds, supporting clients in fields such as nanotechnology, biochemistry, and semiconductor manufacturing. Additionally, TOFWERK collaborates with research laboratories and original equipment manufacturer (OEM) customers to create tailored instrument solutions based on a modular design platform.

Optimal Industrial Automation

Acquisition in 2022
Optimal Industrial Automation is a comprehensive design and build company that specializes in providing software services for various automation systems tailored to diverse clients globally. The company offers a wide range of services, including batch and continuous process automation, electrical services, robotics, product serialization, and training. By functioning as a one-stop shop for automation needs, Optimal Industrial Automation enables clients to streamline their operations and enhance efficiency through its integrated solutions.

PrognomIQ

Venture Round in 2022
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

PreOmics

Series B in 2022
PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Prolab Instruments

Acquisition in 2022
Prolab Instruments is a Swiss technology company that specializes in low-flow, high-precision liquid chromatography systems. The company develops analytical instruments primarily for the pharmaceutical industry, focusing on enhancing the precision and efficiency of liquid chromatography processes. Prolab's proprietary mobile injection unit technology is designed to integrate the injector valve and loop, allowing it to move to each sample vial. This innovative approach minimizes carry-over, thereby improving the accuracy of analytical results. Through its advanced technologies, Prolab Instruments aims to deliver reliable solutions that meet the rigorous demands of pharmaceutical applications.

Molecubes

Acquisition in 2021
MOLECUBES is a spin-off from Ghent University that specializes in the development of modular preclinical imaging systems designed for laboratory environments. Originating from the MEDISIP research group, the company focuses on creating versatile imaging cubes that integrate SPECT, PET, and CT technologies, allowing researchers to conduct high-performance imaging studies on small animals with minimal space requirements. These benchtop platforms are equipped with intuitive wireless acquisition and reconstruction software, making them accessible for users with varying levels of expertise. By prioritizing the needs of end-users, MOLECUBES emphasizes the significance of reliable servicing to enhance the user experience and improve daily imaging practices in preclinical research.

Acuity Spatial Genomics

Acquisition in 2021
Acuity Spatial Genomics specializes in spatial 3D genomic and multiomic analysis, offering a platform that enables simultaneous, genome-wide visualization of the 3D genome in individual cells. Utilizing proprietary technologies such as OligoFISSEQ™ and OligoFISSEQ HD™, the company allows researchers to examine genome organization and 3D chromatin architecture directly in situ. This approach provides a time-efficient and cost-effective means for researchers to gain insights into transcription regulatory programs that influence cell types, states, functions, and disease processes.

Adeptrix

Series A in 2021
Adeptrix is engaged in the development and manufacturing of advanced analytical reagents and assays utilizing its proprietary Bead Assisted Mass Spectrometry (BAMS) platform technology. This innovative platform enables the measurement of immunoassays through MALDI mass spectrometry, facilitating rapid, precise, and sensitive detection of target analytes. BAMS technology supports multiplexing, allowing multiple target analytes to be measured in a single assay, and is high-throughput, capable of processing hundreds to thousands of assays daily. This versatility makes it suitable for a wide array of bio-analytical applications, including drug development, basic research, and clinical diagnostics. Additionally, Adeptrix's cell assay technology focuses on monitoring key proteins and biomarkers essential for advanced drug discovery and disease biology, providing researchers with tools to identify suitable peptides from complex biological mixtures.

Ionpath

Series B in 2020
IonPath, Inc., based in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. Founded in 2014, the company has developed advanced ion beam imaging technology that allows for detailed analysis of tissue biopsies, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) samples. This technology goes beyond traditional light microscopy, providing a comprehensive understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. By enabling healthcare providers to obtain actionable insights, IonPath's services facilitate accurate cancer diagnoses and contribute to advancements in human health.

PrognomIQ

Venture Round in 2020
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Canopy Biosciences

Acquisition in 2020
Canopy Biosciences, founded in 2016 and headquartered in St. Louis, Missouri, is a biotechnology company specializing in research tools for genetic engineering, molecular biology, and personalized medicine. The company offers a comprehensive range of products and services designed to facilitate gene editing, gene expression analysis, and bioprocessing. One of its key technologies, TUNR, targets translation elongation by inserting polyA tracks into specific coding regions of the genome, effectively reducing mRNA levels and suppressing protein expression. This innovative approach supports biomedical researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, accelerating scientific discovery and enhancing the field of genetic engineering. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

PMOD Technologies

Acquisition in 2019
PMOD Technologies LLC, founded in 1993 and based in Zurich, Switzerland, specializes in the development of software quantification tools for biomedical imaging in both human and animal research. Initially created at the University Hospital PET Center in Zurich to address the lack of software for positron emission tomography (PET), the PMOD software evolved through collaborations with engineers from Warsaw University of Technology. This led to the establishment of PMOD Technologies LLC in 2003 as a spin-off to further enhance and distribute the software. The company now serves over 550 sites globally, with more than 1,000 active users, and its offerings have expanded to include tools for functional MRI and CT. PMOD Technologies aims to provide researchers with user-friendly and robust software solutions for various tasks, including kinetic modeling, parametric mapping, and image registration, while ensuring exceptional support and services to facilitate their experimental work. Since July 2019, PMOD Technologies has operated as a subsidiary of Bruker Corporation.

Arxspan

Acquisition in 2019
Arxspan offers a cloud-based suite of applications designed to facilitate project-based research and development collaboration across various industries, including pharmaceuticals, biotechnology, academia, cosmetics, electronics, materials, and chemicals. Their platform allows clients to manage internal research, process incoming data from contract research organizations (CROs), and integrate seamlessly with existing enterprise knowledge management systems. Arxspan's web-based interface supports teams operating both locally and globally, enabling efficient data management and workflow coordination. Key features of their services include electronic lab notebooks, chemistry and biology registration, assay management, inventory control, and centralized data solutions that empower clients to make informed scientific decisions and enhance collaboration with external partners.

Alicona Imaging

Acquisition in 2018
Alicona Imaging is a manufacturer based in Graz, Austria, specializing in optical 3D surface measurement technology. The company focuses on providing advanced metrology systems that measure form and roughness, even in complex and miniaturized geometries. This technology is essential for quality assurance in laboratories and production environments. Alicona Imaging serves various industries, including machine tools, medical technology, forensic science, and microelectronics, enabling clients to enhance product development and optimize processes.

JPK In­stru­ments

Acquisition in 2018
JPK Instruments AG specializes in the manufacture of nano-analytical instruments tailored for life sciences and soft matter applications. The company is known for its atomic force microscopy (AFM) products, which are utilized in diverse fields such as BioAFM, polymer research, surface science, and nanooptics. Additionally, it offers automated force spectroscopy systems that facilitate real-time analysis of molecular interactions at the nanoscale. JPK Instruments also develops force-sensing optical tweezers and 3D particle tracking solutions, which are crucial for quantifying molecular, cellular, and micro-rheological processes. Their products are designed to study various phenomena, including molecular motor mechanics and cell membrane dynamics. Furthermore, the company provides tools to measure single cell-cell and cell-surface interactions under physiological conditions. Founded in 1999 and headquartered in Berlin, Germany, JPK Instruments operates through distributors both domestically and internationally and functions as a subsidiary of Bruker Corporation.

Luxendo

Acquisition in 2017
Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

Hysitron

Acquisition in 2017
Hysitron Incorporated, a subsidiary of Bruker Corporation, specializes in the development, manufacturing, and sale of nanomechanical test instruments designed to measure the mechanical properties of materials at the nanoscale. Established in 1992, Hysitron has been a pioneer in in-situ imaging combined with nanomechanical property measurement, catering to the scientific community for over two decades. Its advanced nanoindentation products are utilized by leading researchers and engineers in materials science, life sciences, and semiconductor applications, supporting innovation and progress in material development.

InVivo Biotech Services

Acquisition in 2017
InVivo Biotech Services is a prominent contract manufacturing organization based in Hennigsdorf, Germany, specializing in the development and production of monoclonal antibodies and recombinant proteins. With over 18 years of experience in mammalian cell culture and protein production, InVivo offers a comprehensive range of biotech services, including cloning, screening, recombinant expression of antigens, generation of hybridoma cell lines, and characterization of antibodies. The company is ISO 9001 certified and serves a diverse clientele, ranging from small university spin-offs to major research institutes and biopharmaceutical companies, providing reliable and cost-effective outsourcing solutions tailored to various needs in the biotechnology sector.

SCiLS

Acquisition in 2017
SCiLS GmbH, based in Bremen, Germany, specializes in developing software solutions for the analysis and exploration of mass spectrometry data. The company offers innovative tools that include statistical analysis software, advanced visualization viewers, and secure cloud-based services designed for collaborative interpretation of complex mass spectrometry imaging (MSI) data sets. As a subsidiary of Bruker Corporation since 2017, SCiLS focuses on enhancing the capabilities of researchers and scientists in interpreting imaging mass spectrometry data through its tailored software applications.

OncoVision

Acquisition in 2016
Oncovision, a Spanish technology start-up established in 2003, specializes in developing medical imaging devices aimed at enhancing cancer diagnosis and treatment. The company focuses on Molecular Vision applied to health sciences, particularly in oncology, neurology, and cardiology. By creating innovative diagnostic tests and multimodal imaging technologies, Oncovision provides healthcare professionals with tools that offer clinical and economic advantages, ultimately improving patient quality of life. The company has garnered recognition for its original technologies and strong intellectual property, receiving accolades from prestigious Spanish and European institutions. Its team, composed of scientists, technicians, and technologists, has contributed to numerous publications and presentations at global medical conferences. Oncovision's advancements in imaging technology position it as a leader in the Spanish and European health industries, with a commitment to pioneering new standards in cancer treatment and care.

Yingsheng Technology

Acquisition in 2016
Yingsheng Technology Pty Ltd. in Brisbane, Australia, that relate to the 3rd generation Advanced Mineral Identification and Characterization System (AMICS) software package, and respective IP for advanced minerals identification and characterization. AMICS is a highly innovative software platform for automated identification and quantification of mineral and synthetic phases. It can be used in conjunction with either scanning electron microscopes (SEM) and SEM-related energy dispersive X-ray spectrometers (EDS), or now also with novel micro X-ray fluorescence (µXRF) analyzers.

Jordan Valley Semiconductors

Acquisition in 2015
Jordan Valley Semiconductors specializes in providing X-ray metrology solutions tailored for the semiconductor industry, addressing both front-end and back-end applications. Founded in 1982, the company offers a diverse range of products, including advanced metrology tools such as the JVX7200 and VUV700U for ultra-thin film measurements, as well as inspection systems like BedeScan for detecting structural defects in wafers. Their technology utilizes various X-ray techniques, such as reflectometry and diffraction, allowing for precise characterization of thin films used in semiconductor manufacturing. The company's solutions cater to applications including wafer level packaging and the production of compound semiconductors. With headquarters in Austin, Texas, Jordan Valley has manufacturing and research facilities in Migdal Ha'Emek, Israel, and Durham, United Kingdom, along with sales and customer support operations across Asia and Europe.

Prairie Technologies

Acquisition in 2013
Prairie Technologies specializes in advanced microscopic imaging products, focusing primarily on laser two-photon and swept field confocal microscopy. The company is recognized for developing the first commercial two-photon system capable of simultaneous imaging and uncaging with dual lasers. Since its founding in 1995, Prairie Technologies has expanded its product offerings to include a range of systems and components, such as two-photon and confocal microscopes, upgrades for older third-party microscopes, UV photolysis systems, and laser launches with AOTF control. The company is committed to supporting its entire product line, from individual components to custom-designed systems, and collaborates with leading scientists and researchers worldwide to meet their evolving needs.

SkyScan

Acquisition in 2012
SkyScan designs, manufactures, markets and services instruments for 3D X-ray micro-CT imaging for customers in materials and life science. SkyScan is located close to Antwerp, Belgium.

Michrom Bioresources

Acquisition in 2011
Michrom Bioresources specializes in the manufacturing of microfluidic products, focusing on liquid chromatography and mass spectrometry equipment. The company offers a range of accessories and consumables tailored for applications in the life sciences, including biotechnology, pharmaceuticals, clinical research, academia, and government laboratories. Notably, Michrom has developed a nanoflow ultra-high performance liquid chromatography system and proprietary CaptiveSpray Ionization sources, which enhance mass spectrometry capabilities, particularly in proteomics and various life science applications.

Accel Instruments GmbH

Acquisition in 2009
ACCEL Instruments GmbH, a privately held supplier of scientific research instruments and proton therapy systems for cancer treatment.

S.I.S. Surface Imaging Systems

Acquisition in 2008
S.I.S. develops, manufactures and distributes advanced atomic force/scanning probe microscopy systems (AFM/SPM) for numerous applications in materials research, including semiconductors, data storage, electronic materials, solar cells, polymers and catalysts. AFM/SPM is a well-established method for ultra-high spatial resolution surface imaging and the characterization of surfaces down to atomic dimensions.

JUWE Laborgeraete

Acquisition in 2008
JUWE Laborgeraete GmbH manufactures analysers and surface area measuring apparatus. The company provides analysers for oxygen, nitrogen, and hydrogen in solids, as well as for carbon and sulphur in ferrous, non-ferrous, and organic materials. It also offers environmental measuring instruments, such as work hygiene, emission measurements, ambient air measurements, and specific surface area determination, as well as systems for water, soil, sludge, and refuse analysis. JUWE Laborgeraete GmbH was founded in 1997 and is based in Viersen, Germany.

Quantron

Acquisition in 2006
Quantron GmbH designs and manufactures optical emission spectrometers for the analysis of metals worldwide. It serves the steel, cast iron, aluminium, solder, and copper industries.

KeyMaster Technologies

Acquisition in 2006
KeyMaster Technologies specializes in the development and manufacture of portable hand-held X-ray fluorescence (XRF) systems designed for a range of applications. The company's offerings include tracer handheld XRF analyzers that utilize Windows CE-based analysis software for spectral analysis, as well as solutions aimed at anti-counterfeiting and brand protection. These systems address security-related challenges by incorporating elemental tagging to secure documents and maintain brand identity. KeyMaster's XRF technology is utilized across various industries, including metals and alloy analysis for metal processing sectors such as automotive, aerospace, and scrap sorting, providing essential tools for positive material identification and quality assurance.

Roentec AG

Acquisition in 2005
Rontec is a manufacturer German of measuring intruments by X-rays. Their specialty are the detectors semiconductors for energy-dispersive x-ray spectroscopy , and in particular the undoped silicon detectors ( silicon sensor diffusion , drift silicon detector ). The doped silicon detectors must be cooled on the one hand to reduce background noise , on the other hand to prevent the migration of dopant; the advantage of undoped detectors is that they need to be much less cooled, especially do not require any liquid nitrogen . They also produce devices implementing these detectors, mostly devices XRF and XRD portable

Princeton Gamma-Tech Instruments

Acquisition in 2005
Princeton Gamma Tech Instruments, Inc. develops and manufactures detection equipment used in the homeland security and industrial markets. The company manufactures gamma-ray and x-ray detectors for the nuclear spectroscopy and research sector. The company is based in Princeton, New Jersey.

Socabim

Acquisition in 2005
Socabim is designs, develops, and markets solutions for X-ray materials research and analytical applications.

VACUUMSCHMELZE

Acquisition in 2003
VACUUMSCHMELZE is a manufacturer specializing in advanced magnetic materials and components. The company develops, produces, and distributes highly specialized magnetic alloys and materials characterized by exceptional magnetic and physical properties. Its diverse product offerings cater to various sectors, including automotive systems, electrical installation technology, energy conversion and distribution, industrial automation and robotics, retail, and renewable energy. With a strong emphasis on innovation and technical expertise, VACUUMSCHMELZE strives to maintain a sustainable competitive advantage in the market.

MAC Science

Acquisition in 2002
MAC Science was founded in 1987, and has become a significant competitor participant in the Japanese in X-ray and thermal analysis instrumentation market. MAC Science focuses on X-ray analysis instrumentation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.